Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.

MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.

MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inhibitors of the hepatic influx transporters organic anion transporting polypeptides (OATP) 1B1 and/or 1B3 may increase the plasma concentrations and adverse effects of atrasentan. In clinical studies, coadministration with the OATP1B1 and 1B3 inhibitor cyclosporine increased the mean systemic exposure (AUC) and peak plasma concentration (Cmax) of atrasentan (single dose, 10 mg) by 380% and 430%, respectively. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination.

MANAGEMENT: Concomitant use of atrasentan with OATP1B1 and/or 1B3 inhibitors should generally be avoided.

Velpatasvir may increase the blood levels of voxilaprevir in some patients. The safety of high levels of voxilaprevir has not been established. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Food may help the absorption of voxilaprevir. You should take this medication with food as directed.